Jonathan B Siegel

Mr. Siegel is the founder and CEO of JBS Healthcare Ventures since its formation in 2017.  In June 2021, he also assumed the role as CEO and Chairman of Board of OPY Acquisition Corp. I, which was a public Nasdaq-listed company between October 2021 and December 2023.  Previously, he was a partner and healthcare sector head at Kingdon Capital Management from 2011 until 2017. Prior to joining Kingdon, Mr. Siegel was a healthcare portfolio manager at SAC Capital Advisors from 2005 until 2011; an associate director of pharmaceutical and specialty pharmaceutical research at Bear, Stearns & Co.; a pharmaceuticals research associate at Dresdner Kleinwort Wasserstein; and a consultant in the Life Sciences division of Computer Sciences Corporation.

Mr. Siegel has worked as a research associate at the Novartis Center for Immunobiology at Harvard Medical School, and a research assistant at Tufts University School of Medicine. He is also currently a director at Jaguar Health, Inc. a Nasdaq listed company. He has served on the board of advisors of Vitalis LLC, a private pharmaceutical company since March 2019, and as a director of Napo Therapeutics S.p.A, the majority owned Italian subsidiary of Napo Pharmaceuticals and Jaguar Health, Inc. since November 2021. He served on the Board of Directors of Sol-Gel Technologies Ltd, a Nasdaq listed company from 2018 to 2024 and previously Lumara Health until it was acquired by AMAG Pharmaceuticals in 2014.

Mr. Siegel received a BS in psychology from Tufts University in 1995 and an MBA from Columbia Business School in 1999.